Pugliese Nicola, Roda Giulia, Peyrin-Biroulet Laurent, Danese Silvio
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Department of Hepato-Gastroenterology and Inserm U954, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Expert Opin Emerg Drugs. 2020 Mar 9:1-9. doi: 10.1080/14728214.2020.1737009.
: Ulcerative colitis (UC) is a chronic idiopathic autoimmune inflammatory disorder, primarily affecting the gastrointestinal system. There are many patients affected that do not respond well to therapy and many others to which there is a loss of efficacy every year. The proportion of patients who have already experienced anti-TNF therapy is constantly increasing, making the development of new drugs with alternative mechanisms of action an important need for the treatment of UC.: This review aims on emerging drugs in the treatment of UC and reviews data on their efficacy and safety.: UC, for many years, comparatively to CD, received little attention for several possible reasons, especially because it was not considered as a progressive disease able to induce irreversible bowel damage. This has led to lower investments by the scientific community and a slower development of therapeutic options for UC. In the past few years, this trend has started to change. In fact, new promising drugs have been developed and others are emerging with positive results. Although many treatment modalities have recently been approved, additional drugs are currently being investigated and will probably be part of the UC treatment regimen in the coming years.
溃疡性结肠炎(UC)是一种慢性特发性自身免疫性炎症性疾病,主要影响胃肠道系统。有许多患者对治疗反应不佳,还有许多患者每年都会出现疗效丧失的情况。已经接受抗TNF治疗的患者比例在不断增加,因此开发具有替代作用机制的新药成为治疗UC的一项重要需求。
本综述旨在介绍治疗UC的新兴药物,并综述其疗效和安全性数据。
多年来,与克罗恩病(CD)相比,UC由于多种可能的原因很少受到关注,尤其是因为它不被认为是一种能够导致不可逆肠道损伤的进行性疾病。这导致科学界的投资减少,UC治疗方案的开发也较为缓慢。在过去几年中,这种趋势开始改变。事实上,已经开发出了一些有前景的新药,还有其他一些新药也取得了积极成果。尽管最近已经批准了许多治疗方式,但目前仍在研究其他药物,这些药物可能会在未来几年成为UC治疗方案的一部分。